Comparison of the placebo arms of three prospective trials in patients with nonmetastatic castration‐resistant prostate cancer
aIn multivariate analysis, baseline PSA >10 ng/mL was significantly associated with shorter bone metastasis‐free survival (RR: 2.96). High PSA velocity was significantly associated with shorter time to first bone metastasis (RR: 1.47 for each year increase in velocity).
bIn multivariate analysis, PSA ≥3.1 ng/mL was significantly associated with time to first bone metastasis (RR: 1.98) and bone metastasis‐free survival (RR: 1.98).
cA total of 48% had dual risk factors of PSA ≥8 ng/mL and PSADT ≤10 months; 52% had a single risk factor.
dApproximate values were extrapolated from Kaplan‐Meier curves.
Abbreviations: NA, not available; NR, not reached; PSA, prostate‐specific antigen; PSADT, prostate‐specific antigen doubling time; RR, relative risk.
Comparison of the placebo arms of three prospective trials in patients with nonmetastatic castration‐resistant prostate cancer
aIn multivariate analysis, baseline PSA >10 ng/mL was significantly associated with shorter bone metastasis‐free survival (RR: 2.96). High PSA velocity was significantly associated with shorter time to first bone metastasis (RR: 1.47 for each year increase in velocity).
bIn multivariate analysis, PSA ≥3.1 ng/mL was significantly associated with time to first bone metastasis (RR: 1.98) and bone metastasis‐free survival (RR: 1.98).
cA total of 48% had dual risk factors of PSA ≥8 ng/mL and PSADT ≤10 months; 52% had a single risk factor.
dApproximate values were extrapolated from Kaplan‐Meier curves.
Abbreviations: NA, not available; NR, not reached; PSA, prostate‐specific antigen; PSADT, prostate‐specific antigen doubling time; RR, relative risk.
